UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): February 22, 2018

                               CEL-SCI CORPORATION
               --------------------------------------------------
             (Exact name of Registrant as specified in its charter)


        Colorado                      001-11889                  84-0916344
  --------------------            -------------------        -----------------
(State or other jurisdiction     (Commission File No.)      (IRS Employer
of incorporation)                                            Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
               --------------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
               --------------------------------------------------
          (Former name or former address if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-14c))

Indicate by check mark whether the  registrant is an emerging  growth company as
defined in Rule 405 of the Securities  Act of 1933  (ss.203.405 of this chapter)
or Rule  12b-2 of the  Securities  Exchange  Act of 1934  (ss.204.12b-2  of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange  Act.  [ ]

                                       1
<PAGE>

Item  3.03.  Material  Modification  to Rights  of  Security Holders.

     On February 22, 2018 the Company extended the expiration date of its Series
DD and Series EE warrants to July 1, 2018.  The Series DD and Series EE warrants
were issued on December 8, 2016. As a result of the reverse stock split approved
by the Company's shareholders and adopted by the Company's directors,

     o    the  holders  of the  Series DD  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share, and

     o    the  holders  of the  Series EE  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share









                                       2
<PAGE>



                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  February 23, 2018               CEL-SCI CORPORATION



                                       By: /s/ Geert Kersten
                                          --------------------------------
                                          Geert Kersten
                                          Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8k303warrantext2-18.txt", "description": "8-K ITEM 3.03", "secsgml_size_bytes": 4003}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "18636699"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): February 22, 2018

                               CEL-SCI CORPORATION
               --------------------------------------------------
             (Exact name of Registrant as specified in its charter)

        Colorado                      001-11889                  84-0916344
  --------------------            -------------------        -----------------
(State or other jurisdiction     (Commission File No.)      (IRS Employer
of incorporation)                                            Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
               --------------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
               --------------------------------------------------
          (Former name or former address if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-14c))

Indicate by check mark whether the  registrant is an emerging  growth company as
defined in Rule 405 of the Securities  Act of 1933  (ss.203.405 of this chapter)
or Rule  12b-2 of the  Securities  Exchange  Act of 1934  (ss.204.12b-2  of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange  Act.  [ ]

                                       1
Item  3.03.  Material  Modification  to Rights  of  Security Holders.

     On February 22, 2018 the Company extended the expiration date of its Series
DD and Series EE warrants to July 1, 2018.  The Series DD and Series EE warrants
were issued on December 8, 2016. As a result of the reverse stock split approved
by the Company's shareholders and adopted by the Company's directors,

     o    the  holders  of the  Series DD  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share, and

     o    the  holders  of the  Series EE  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  February 23, 2018               CEL-SCI CORPORATION

                                       By: /s/ Geert Kersten
                                          --------------------------------
                                          Geert Kersten
                                          Chief Executive Officer